Olpasiran clinical trials
Olpasiran is named as an intervention in 3 current clinical trials in our USA, Australia, China, Germany, France, Spain, Italy, Canada, Japan, Netherlands, Denmark, Sweden, Poland, Austria, Czechia, Norway, Brazil, Mexico, South Korea and Taiwan registers. 2 are recruiting patients now. All registered phases are Phase 3. The lead sponsor is Amgen. The most-studied condition is Cardiovascular Disease.
How Olpasiran works
All drug targets →- LPA mRNA rnai inhibitor Rnai inhibitorTarget: LPA lipoprotein(a)ChEMBL only
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4650413, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13709, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Olpasiran
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Olpasiran
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012 · Cardiovascular Disease
|
Phase 3 | Recruiting | Amgen | USA, Canada, Australia |
|
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260 · Cardiovascular Disease
|
Phase 3 | Recruiting | Amgen | USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Canada, Japan, Australia |
|
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303 · Atherosclerotic Cardiovascular Disease
|
Phase 3 | Active, closed | Amgen | USA, China, Germany, France, Spain, Italy, Sweden, Poland, Austria, Czechia, Norway, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Olpasiran
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Amgen | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Olpasiran trials
How many clinical trials are testing Olpasiran?
3 current trials in our USA, Australia, China, Germany, France, Spain, Italy, Canada, Japan, Netherlands, Denmark, Sweden, Poland, Austria, Czechia, Norway, Brazil, Mexico, South Korea and Taiwan registers name Olpasiran (also registered as AMG 890) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Olpasiran trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Australia, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 2 with sites in Canada, 1 with sites in Japan, 1 with sites in Netherlands and 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Olpasiran clinical trials?
The lead sponsor is Amgen. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Olpasiran works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Olpasiran works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Olpasiran (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.